{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:10:13Z","timestamp":1780395013688,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100019559","name":"Carl von Ossietzky Universit\u00e4t Oldenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Wir berichten \u00fcber eine 48-j\u00e4hrige Patientin mit mittelschwerer Plaquepsoriasis und Lupus erythematodes tumidus (LET), die unter Deucravacitinib 6\u202fmg\/Tag eine rasche Besserung des LET sowie eine deutliche Verbesserung der Plaquepsoriasis zeigte. Die Kasuistik verdeutlicht die potenzielle Wirksamkeit des Tyrosinkinase\u00a02(TYK2)-Inhibitors Deucravacitinib bei Patienten mit Lupus erythematodes tumidus.<\/jats:p>","DOI":"10.1007\/s00105-026-05713-2","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:26:56Z","timestamp":1780392416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erfolgreiche Behandlung eines Lupus erythematodes tumidus (LET) mit Deucravacitinib bei einer Patientin mit gleichzeitig vorliegender Plaquepsoriasis","Successful treatment of lupus erythematosus tumidus (LET) with deucravacitinib in a\u00a0patient with concomitant plaque psoriasis"],"prefix":"10.1007","author":[{"given":"Tim","family":"Schricker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Matiszick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Raap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Patsinakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"9","key":"5713_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.941003","volume":"23","author":"A Verdelli","year":"2022","unstructured":"Verdelli\u00a0A, Corr\u00e0\u00a0A, Mariotti\u00a0EB et\u00a0al (2022) An update on the management of refractory cutaneous lupus erythematosus. Front Med 23(9):941003","journal-title":"Front Med"},{"issue":"10","key":"5713_CR2","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1007\/s10067-025-07597-4","volume":"44","author":"J Chen","year":"2025","unstructured":"Chen\u00a0J, Yin\u00a0X, Kan\u00a0X et\u00a0al (2025) A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis. Clin Rheumatol 44(10):4025\u20134032","journal-title":"Clin Rheumatol"},{"issue":"19","key":"5713_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199447","volume":"26","author":"Y Mima","year":"2025","unstructured":"Mima\u00a0Y, Yamamoto\u00a0M, Iozumi\u00a0K (2025) Review of promising off-label use of deucravacitinib. Int J Mol Sci 26(19):9447","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5713_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54559-6","volume":"15","author":"T Seremet","year":"2024","unstructured":"Seremet\u00a0T, Di Domizio\u00a0J, Girardin\u00a0A et\u00a0al (2024) Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases. Nat Commun 15(1):10688","journal-title":"Nat Commun"},{"issue":"6","key":"5713_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/bjd\/ljaf293","volume":"193","author":"S Wasserer","year":"2025","unstructured":"Wasserer\u00a0S, Seiringer\u00a0P, Kurzen\u00a0N et\u00a0al (2025) Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus. Br J Dermatol 193(6):1192\u20131203","journal-title":"Br J Dermatol"},{"issue":"3","key":"5713_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103723","volume":"24","author":"LA Bokor","year":"2025","unstructured":"Bokor\u00a0LA, Martyin\u00a0K, Krebs\u00a0M et\u00a0al (2025) Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules \u2013 A systematic review and meta-analysis. Autoimmun Rev 24(3):103723","journal-title":"Autoimmun Rev"},{"issue":"1","key":"5713_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.33590\/emjdermatol\/ZOFM4548","volume":"13","author":"EM Murase","year":"2025","unstructured":"Murase\u00a0EM, Adams\u00a0PE, Murase\u00a0JE (2025) Refractory ulcerative lupus chilblains treated with deucravacitinib: A\u00a0case report and review of the literature. EMJ Dermatol 13(1):135\u2013139","journal-title":"EMJ Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05713-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05713-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05713-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:26:57Z","timestamp":1780392417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05713-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":7,"alternative-id":["5713"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05713-2","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Schricker, A.\u00a0Matiszick, U.\u00a0Raap und N.\u00a0Patsinakidis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}